Longevity public stocks are investable: here’s a DLT Chatbot guide

How DLT’s chatbot turns fragmented public market data into a structured view of the companies driving the next generation of biotech.

Chatbot prompts to access highly curated data

Example DLT Chatbot prompt

When you access DLT, you can use the chatbot to run a query like this: “I want to build a longevity investment portfolio of publicly quoted aging disease and longevity biotech companies, provide me with a balanced portfolio recommendation across all public markets.”

Chatbot results

The opportunity is less about “living forever” and more about treating the diseases of aging by targeting the underlying biology that drives them. The challenge for public-market investors is that this theme is hard to index: many companies doing relevant work don’t call themselves longevity companies, and many companies that do adopt the label can be early-stage and volatile.

That’s why a practical longevity portfolio needs a disciplined search process; one that starts with biology, not buzzwords.

A mechanism-first way to search for longevity exposure

Most public biotechs are categorized by disease area: neurology, oncology, immunology, cardiometabolic disease, rare disease. Longevity cuts across all of them. Instead of screening for the word “aging,” I built the portfolio around the hallmarks of aging; recurring biological failure modes such as cellular senescence, chronic inflammation, loss of proteostasis, mitochondrial dysfunction, epigenetic alterations, telomere attrition, and altered intercellular communication.

This matters for investors because hallmarks behave like upstream drivers. A platform that can modulate one hallmark may create multiple shots on goal across several diseases and organs. In other words, a mechanism-first lens can reveal pipeline optionality that a disease-label lens hides.

The investable constraint: public-only, and every holding must matter

Biotech investing is defined by non-linear outcomes: one clinical readout can reshape a company’s value overnight. The easiest way to blow up a longevity portfolio is to accidentally build a concentrated bet on one modality, one disease area, or a handful of binary trials.

So a portfolio construction uses two constraints:

1. Publicly held only (investable via public markets).
2. Minimum 3% per position, so each holding is meaningful, while still limiting single-name concentration.

The result is a sleeve-based structure designed to diversify how returns can happen:

• Core clinical exposure: companies with broader pipelines and meaningful clinical-stage activity, intended to anchor volatility.
• Regeneration sleeve: cell and tissue repair exposure to diversify away from small-molecule-only approaches.
• Platform/AI sleeve: scaled discovery engines that can generate multiple candidates over time; more “experiments” running in parallel.
• Optionality sleeve: smaller, higher-upside exposures sized so no single event dominates the portfolio.

Why include an AI-driven discovery company?

Aging biology is complex and highly interconnected. In that environment, repeatability matters. This is one reason to include a platform-driven name like Insilico Medicine in a longevity portfolio: the investment thesis is not a single program, but the ability to repeatedly generate and advance new candidates across diverse targets and indications. Platform exposure won’t eliminate trial risk, but it can change the portfolio’s profile from “one big bet” to “many ongoing bets.”

The portfolio (balanced; 15 holdings; ≥3% each)

Investing in shares and other investments involves risk, including the potential loss of some or all of the capital invested:

CONSIDER: Core clinical exposure (49%)

• Alnylam Pharmaceuticals (14%)
• Denali Therapeutics (9%)
• Mesoblast (9%)
• Anavex Life Sciences (6%)
• Regenxbio (5%)
• Amylyx Pharmaceuticals (3%)
• Alector (3%)

CONSIDER: Regeneration / cell & tissue repair sleeve (21%)

• Celularity (7%)
• SanBio (7%)
• FibroBiologics (7%)

CONSIDER: Platform / AI discovery sleeve (16%)

• Insilico Medicine (10%)
• Recursion Pharmaceuticals (6%)

CONSIDER: Optionality sleeve (14%)

• BioAge Labs (5%)
• Arvinas (5%)
• Telomir Pharmaceuticals (4%)

This mix is intentionally not “pure longevity marketing.” It is a public-market attempt to own multiple routes to progress in aging biology: RNA and gene-based approaches, neurodegeneration exposure, regenerative medicine, protein-level interventions, and scaled discovery.

How to manage it: simple rules beat strong opinions

A longevity biotech basket will be volatile. The point is not to avoid drawdowns; it’s to avoid having one drawdown become permanent.

A practical maintenance approach:

• Rebalance quarterly (or semiannually if you prefer lower turnover).
• Use drift bands (e.g., rebalance when a holding moves ±25–35% relative to its target weight).
• Avoid “event trading” unless your thesis changes (one trial readout is information; it shouldn’t automatically force a portfolio-wide redesign).

The takeaway

Longevity investing isn’t one trade. It’s a pipeline and diversification problem. A mechanism-first screen can surface relevant exposure that disease labels miss, and a sleeve-based portfolio can spread risk across modalities and stages while keeping every holding meaningful. The result is a public-market longevity portfolio built to survive the field’s reality: progress is real, timelines are long, and outcomes arrive in discrete, often surprising steps.

---

This article is provided for general information and educational purposes only and does not constitute investment, financial, legal, tax or any other form of advice. It is not a financial promotion for any specific investment, does not take into account the individual circumstances, objectives or needs of any reader, and should not be treated as a personal recommendation to buy, sell or hold any investment or to adopt any particular strategy.

The content may include commentary on publicly traded securities and investment strategies but has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is therefore classified as a marketing communication. Any opinions expressed reflect the author’s judgement at the time of writing, are subject to change without notice, and no representation or warranty is given as to the accuracy, completeness or reliability of any information, forecasts or projections contained herein.

Investing in shares and other investments involves risk, including the potential loss of some or all of the capital invested. Past performance is not a reliable indicator of future results, and the value of investments and the income derived from them can go down as well as up. Readers are responsible for their own investment decisions and should consider whether any investment is suitable for their circumstances and, where appropriate, seek advice from an independent, FCA‑authorised financial adviser.

To the fullest extent permitted by law, neither the author nor the publisher accepts any responsibility or liability for any direct or indirect loss or damage arising out of or in connection with the use of, or reliance on, the information contained in this article.

Disclaimer

Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. First Longevity is targeted exclusively at sophisticated investors who understand these risks and make their own investment decisions. Investment opportunities have not been approved as financial promotions and are not covered by the Financial Services Compensation Scheme (FSCS) and you may not have access to the Financial Ombudsman Service (FOS). If you are in any doubt about the action you should take or the contents of any of the Financial Promotion received, you should contact your stockbroker, solicitor, accountant, bank manager or other professional adviser authorised under the Financial Services and Markets Act 2000, who specialises in advising on bonds, shares and other securities, including unlisted securities.

Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status.